Searchable abstracts of presentations at key conferences in endocrinology

ea0014s17.1 | Somatostatin receptors in health and disease | ECE2007

Pro and contra of SRIF analogue therapy in pituitary tumors

van der Lely AJ

Long-acting somatostatin analogues normalize serum IGF-I levels in about 65% of acromegalic patients. Somatostatin analogs reduce GH secretion but also induce GH resistance of the liver because of low portal insulin levels; i.e. patients have a relative high GH level and a GH resistance of the liver which results in a relative low IGF-I action because of high IGFBP1 levels, but the other tissues still have normal GH sensitivity. One might predict that long-term follow-up of tr...

ea0081p5 | Adrenal and Cardiovascular Endocrinology | ECE2022

Group education programme for patients with adrenal insufficiency: evaluation based on patients experiences

Davidse Kirsten , Geilvoet Wanda , Brinkman Lotte , van Eck J.P. , Feelders Richard , Van der Lely Aart Jan

Introduction: Adequate hormone replacement therapy in adrenal insufficiency is essential. Patients should have basic knowledge about their condition and what to do in situations which could trigger an adrenal crisis. Education on how and when hydrocortisone replacement therapy should be adjusted as well as instruction and practice an emergency injection are considered important measures to prevent an adrenal crisis. A standardized nurse-led group-based education programme (GEP...

ea0081p148 | Pituitary and Neuroendocrinology | ECE2022

AZP-3813, a bicyclic 16-amino acid peptide antagonist of the human growth hormone receptor as a potential new treatment for acromegaly

Milano Stephane , Kurasaki Haruaki , Tomiyama Tatsuya , Reid Patrick , Jan Van der Lely Aart , Culler Michael D.

Medical treatment of acromegaly is based on either suppressing pituitary GH secretion or inhibiting GH action by preventing interaction with its receptor in order to suppress the elevated levels of IGF1. AZP-3813 is a 16-amino acid, bicyclic peptide antagonist of the GH receptor (GHR) derived from peptide sequences discovered using a unique, cell-free in vitro transcription-translation system screened against the human GHR, and that was optimized by rational design to increase...

ea0063oc6.1 | Obesity | ECE2019

Impaired glucose homeostasis in leptin-deficient ob/ob mice is corrected by AZP-3404, a 9-amino acid peptide analog derived from insulin-like growth factor-binding protein 2, a key mediator of leptin action

Culler Michael D , Delale Thomas , Milano Stephane , van der Lely Aart Jan , Abribat Thierry , Clemmons David

The key metabolic hormone, leptin, acts in part through the liver to regulate glucose homeostasis, as well as the maturation of both adipocytes and osteoblasts. These actions have been demonstrated to be mediated by insulin-like growth factor binding protein 2 (IGFBP-2), independent of its ability to bind IGF1. The effects of IGFBP-2 on adipocyte and osteoblast maturation can be localized to a short peptide sequence within the unique heparin binding domain (HBD-1) of IGFBP-2. ...

ea0049gp174 | Pituitary | ECE2017

Efficacy and safety of switching to pasireotide LAR alone or in combination with pegvisomant in acromegaly patients controlled with combination treatment of first-generation somatostatin analogues and weekly pegvisomant (PAPE study): a prospective open-label 48 week study, preliminary results 24 weeks

Muhammad Ammar , van der Lely Aart Jan , Janssen Joop , Neggers Sebastian

Background: Efficacy and safety of combination treatment of pasireotide LAR with pegvisomant (PEGV) has not been studied yet. Switching to Pasireotide LAR in patients previously controlled with long-acting somatostatin analogues (LA-SSAs) and PEGV could reduce the required PEGV dose to normalize serum IGF1 levels, while the effect on glucose metabolism is unknown.Methods: We enrolled 60 acromegaly patients >18 years with acromegaly who had normal IGF...

ea0037oc11.4 | Obesity | ECE2015

Unacylated ghrelin and its analogue AZP-531 suppress ghrelin induced fat accumulation and feeding behaviours in high-fat diet fed male rats

Scholte Jan , Scheurink Anton , Abribat Thierry , Julien Michel , Themmen Axel , van der Lely AJ , Delhanty Patric

The peptides acylated and unacylated ghrelin (AG and UAG) are produced predominantly in the stomach. AG is the only known circulating orexigenic hormone with obesogenic and insulin-desensitising properties. Recent evidence suggests that UAG can inhibit these activities of AG. To investigate potential inhibitory effects of UAG and AZP-531, a UAG analogue, on AG-induced appetite and obesity we used an established rat model of diet induced obesity. Animals were fed a high-fat die...

ea0070aep400 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Systematic screening reveals large number of undiagnosed and untreated cardiovascular risk factors in adults with prader-willi syndrome

Pellikaan Karlijn , Rosenberg Anna , Davidse Kirsten , Jan Van der Lely Aart , De Graaff Laura

Introduction: Prader-Willi syndrome (PWS) is a complex hypothalamic disorder, combining hypotonia, intellectual disability (ID), pituitary hormone deficiencies and hyperphagia. In PWS, up to 3% of patients die every year. In half of the patients, the cause of death is obesity related and / or of cardiovascular origin. Obesity is caused by hyperphagia combined with a low energy expenditure. Untreated hormone deficiencies like hypogonadism and hypothyroidism can cause low muscle...

ea0070aep670 | Pituitary and Neuroendocrinology | ECE2020

Eucaloric very low-carbohydrate ketogenic diet as a new supportive treatment modality for acromegaly?

Coopmans Eva , Berk Kirsten AC , El-Sayed Nour , Neggers Sebastian , Van der Lely Aart Jan

Objective: Acromegaly is caused by a growth hormone (GH)-secreting pituitary tumor and its signs are linked to increasedGH-dependent hepatic insulin-like growth factor I (IGF-I) synthesis. A eucaloric very low-carbohydrate ketogenic diet (euVLCK; < 50 g/day) induces ketosis and reduces portal insulin concentrations, which down-regulate hepatic GH receptors and reduce IGF-I synthesis. Somatostatin receptor ligands (SRLs) reduce GH secretion by the pituitary tumor,resul...

ea0032p695 | Neuroendocrinology | ECE2013

Des-acyl ghrelin acts directly and independently and counteracts acyl-ghrelin-induced neuronal activity in the central melanocortin system of rats

Stevanovic Darko , Delhanty Patric , Themmen Axel , Popovic Vera , Holstege Joan , van der Lely Aart-Jan

Ghrelin, the endogenous GH secretagogue, has an important role in metabolic homeostasis. It exists in two major molecular forms: acylated (AG) and des-acylated (DAG). Many studies suggest different roles for these two forms in energy balance regulation. In the present study, we compared the effects of acute intracerebroventricular (ICV) administration of AG, DAG and their combination (AG+DAG) to young adult Wistar rats on food intake and central melanocortin system modulation....

ea0032p855 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Long-term efficacy of long-acting somatostatin analogues in combination with pegvisomant in 112 acromegaly patients, a retrospective single centre study with follow up for up to 8 years

Franck Sanne , van der Lely Aart-Jan , de Rijke Yolanda , Neggers Sebastian

Introduction: Pegvisomant (PEGV) has an efficacy of >90% to control insulin-like growth factor (IGF-1), however in everyday practice a limited efficacy of 63% was reported.Aim: To assess efficacy in the largest single center cohort of acromegalics using PEGV.Methods: A 112 subjects (65 male) were not controlled with high-dose somatostatin analogues (LA-SRIF) for at least 6 months. To control acromegaly, 109 subjects added PEGV ...